Other potential therapies include the following: artesunate mitigating doxorubicin-induced HF via the SIRT1/FOXO3a/MnSOD pathway [33]; inhibition of p53 acetylation improving pressure overload-induced CMD and HFpEF [190]; Supplementation with nicotinamide riboside can restore the NAD+/NADH ratio and reduce the acetylation levels of mitochondrial proteins, thereby improving mitochondrial function and the HFpEF phenotype [191]. The gene discussed is SIRT1; the disease is hydrops fetalis.